MELANOMA DRUG WITHHELD
Health News Ireland hears how yet another potential life-saving drug is not being reimbursed because of financial considerations…
MALIGNANT Melanoma is a particularly nasty and dangerous form of skin cancer. Once it starts to spread, it can overwhelm a body in as little as 6-9 months. Compared with other forms of the disease, malignant melanoma strikes those who are relatively young and, on average, 22 years of life is lost from each victim.
So, the question is: what would you give for a drug that could safeguard you against this deadly scourge? The answer, for those who have the disease, is everything!
Well, the good news is…we have that drug. The bad news is…this being Ireland, you can’t have it!!
The drug in question is called YERVOY (medical name: ipilimumab). It is particularly effective and works by stimulating the body’s own immune system to identify and fight spreading melanoma cancer cells. The drug is so powerful that it has been classified as ‘twice as effective’ as its nearest competitor drug.
It is the first significant treatment advance in this form of cancer for more than 30 years.
YERVOY has been approved for use by the European medical authorities since July of last year. In January of this year, the National Cancer Care Control Programme (NCCP) recommended to the Health Service Executive (HSE) that funding should be made available to provide the drug to Irish patients.
Devastating Consequences
But, this has still not happened. In fact, the National Centre for Pharmacoeconomics (NCPE) has refused to recommend the reimbursement of YERVOY on the basis of cost. Like most things in Ireland today, it comes down to money.
Doctors here are pointing out that the delay is having devastating consequences for Irish patients with advanced melanoma and is causing untold misery for their families.
“We in the oncology community have waited a long time for a new effective therapy option like ipilimumab. The prolonged disease control we have seen in a few of these patients is unprecedented in this cancer and it is therefore very disheartening that patients in Ireland are unable to access this exciting therapy,” said Dr Cathy Kelly of the Mater Hospital’s BreastCheck unit.
Professor John Crown – a well-known cancer specialist and TD – has said that the drug can work really well for some patients.
Deaths from malignant melanoma have increased steadily over the years in Ireland. If it spreads to other areas of the body, you have a major fight on your hands.
Other European countries, including England, Denmark and Holland have made YERVOY available to patients. But not Ireland.
BMS, the company who make the drug, have written to the Minister for Health on the matter. They have also written to the Taoiseach. They await a reply. And while we wait, people are dying.
MALIGNANT Melanoma is a particularly nasty and dangerous form of skin cancer. Once it starts to spread, it can overwhelm a body in as little as 6-9 months. Compared with other forms of the disease, malignant melanoma strikes those who are relatively young and, on average, 22 years of life is lost from each victim.
So, the question is: what would you give for a drug that could safeguard you against this deadly scourge? The answer, for those who have the disease, is everything!
Well, the good news is…we have that drug. The bad news is…this being Ireland, you can’t have it!!
The drug in question is called YERVOY (medical name: ipilimumab). It is particularly effective and works by stimulating the body’s own immune system to identify and fight spreading melanoma cancer cells. The drug is so powerful that it has been classified as ‘twice as effective’ as its nearest competitor drug.
It is the first significant treatment advance in this form of cancer for more than 30 years.
YERVOY has been approved for use by the European medical authorities since July of last year. In January of this year, the National Cancer Care Control Programme (NCCP) recommended to the Health Service Executive (HSE) that funding should be made available to provide the drug to Irish patients.
Devastating Consequences
But, this has still not happened. In fact, the National Centre for Pharmacoeconomics (NCPE) has refused to recommend the reimbursement of YERVOY on the basis of cost. Like most things in Ireland today, it comes down to money.
Doctors here are pointing out that the delay is having devastating consequences for Irish patients with advanced melanoma and is causing untold misery for their families.
“We in the oncology community have waited a long time for a new effective therapy option like ipilimumab. The prolonged disease control we have seen in a few of these patients is unprecedented in this cancer and it is therefore very disheartening that patients in Ireland are unable to access this exciting therapy,” said Dr Cathy Kelly of the Mater Hospital’s BreastCheck unit.
Professor John Crown – a well-known cancer specialist and TD – has said that the drug can work really well for some patients.
Deaths from malignant melanoma have increased steadily over the years in Ireland. If it spreads to other areas of the body, you have a major fight on your hands.
Other European countries, including England, Denmark and Holland have made YERVOY available to patients. But not Ireland.
BMS, the company who make the drug, have written to the Minister for Health on the matter. They have also written to the Taoiseach. They await a reply. And while we wait, people are dying.








